VC  DEFTA Partners

     Office Locations:

111 Pine Street, Suite 1410
San Francisco, CA 94111-5616
Phone: 415-433-2262
Fax: 415-433-2264



  • Early
  • Seed



  • Information Technology
  • Life Sciences & Healthcare



    DEFTA Partners is a leading venture capital firm focusing on innovative technologies in IT and healthcare. Since the 1980s, DEFTA Partners has invested in more than 100 companies in the U.S., U.K., Israel, Bangladesh, and Japan. DEFTA's investments normally range from $500,000 to $3 million, however, the firm has the flexibility to invest outside this range, should the right opportunity present itself. DEFTA takes a hands on approach and plays an active role with its portfolio companies.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Elona Baum Managing Director
    George Hara Group Chairman and CEO
    Kyoko Watanabe Managing Director
    Masa Isono CFA Principal


    Recent Funding Events (trailing 12 months):







      Actuate Therapeutics



      Series B-3


      BioEclipse Therapeutics



      Series A-1


      Actuate Therapeutics



      Series B


    Portfolio companies include:

        web link

      Actuate Therapeutics
        web link

      BioEclipse Therapeutics
        web link

        web link

        web link

        web link

        web link

        web link


    Recent News: